Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up
Purpose. To report long-term visual and anatomical outcomes in eyes with neovascular age-related macular degeneration (nAMD) treated with a treat-and-extend regimen (TER) of intravitreal antivascular endothelial growth factor (anti-VEGF) injections in real-world settings. Methods. Retrospective coho...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2020/3207614 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546806623371264 |
|---|---|
| author | Simon Javidi Ali Dirani Fares Antaki Marc Saab Sofiane Rahali Ghassan Cordahi |
| author_facet | Simon Javidi Ali Dirani Fares Antaki Marc Saab Sofiane Rahali Ghassan Cordahi |
| author_sort | Simon Javidi |
| collection | DOAJ |
| description | Purpose. To report long-term visual and anatomical outcomes in eyes with neovascular age-related macular degeneration (nAMD) treated with a treat-and-extend regimen (TER) of intravitreal antivascular endothelial growth factor (anti-VEGF) injections in real-world settings. Methods. Retrospective cohort study of consecutive patients with nAMD treated with a TER of anti-VEGF intravitreal injections by a single retina specialist (GC). Patients with nAMD who had at least one year of follow-up were identified using an electronic database. Best-corrected visual acuity (BCVA), comprehensive ophthalmologic examination, and macular OCT were performed at each visit. Patients received a loading dose of three monthly intravitreal injections and then were treated according to a TER of bevacizumab, ranibizumab, and/or aflibercept. The number of injections, BCVA, and central retinal thickness (CRT) were evaluated during the follow-up period. Results. 180 eyes from 180 patients were included in the study. Mean age was 75 ± 9 (range: 51–96). Mean BCVA was 0.77 ± 0.64 LogMAR at baseline, 0.69 ± 0.58 LogMAR (p=0.0057) after loading phase, 0.64 ± 0.55 LogMAR (p=0.0001) after 6 months of TER, and 0.76 ± 0.71 LogMAR after 6 years of treatment (n = 32 at year 6). CRT decreased significantly after the loading phase (p=0.0002). The mean number of intravitreal injections per year was 7.6 during the first three years of treatment and then decreased to 5.9 during year 4 to 7. Conclusions. This retrospective study of 180 nAMD patients treated with a TER of intravitreal anti-VEGF demonstrates an initial improvement of BCVA after loading phase, followed by long-term visual stabilization for at least six years. These results were obtained with a high number of injections, averaging close to six injections per year during long-term follow-up. In light of the natural evolution of nAMD, these data support the long-term efficacy of this treatment under real-world conditions of heterogeneity of patients and type of anti-VEGF used. |
| format | Article |
| id | doaj-art-5ceae41a52704bc4a82ec7813c2626c2 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-5ceae41a52704bc4a82ec7813c2626c22025-02-03T06:47:05ZengWileyJournal of Ophthalmology2090-004X2090-00582020-01-01202010.1155/2020/32076143207614Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-UpSimon Javidi0Ali Dirani1Fares Antaki2Marc Saab3Sofiane Rahali4Ghassan Cordahi5Centre Universitaire d’Ophtalmologie, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal, QC, CanadaCentre Universitaire d’Ophtalmologie, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal, QC, CanadaCentre Universitaire d’Ophtalmologie, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal, QC, CanadaDépartement d’ophtalmologie, Hôpital Charles-Le Moyne, Université de Sherbrooke, Greenfield Park, QC, CanadaCentre Universitaire d’Ophtalmologie, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal, QC, CanadaCentre Universitaire d’Ophtalmologie, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal, QC, CanadaPurpose. To report long-term visual and anatomical outcomes in eyes with neovascular age-related macular degeneration (nAMD) treated with a treat-and-extend regimen (TER) of intravitreal antivascular endothelial growth factor (anti-VEGF) injections in real-world settings. Methods. Retrospective cohort study of consecutive patients with nAMD treated with a TER of anti-VEGF intravitreal injections by a single retina specialist (GC). Patients with nAMD who had at least one year of follow-up were identified using an electronic database. Best-corrected visual acuity (BCVA), comprehensive ophthalmologic examination, and macular OCT were performed at each visit. Patients received a loading dose of three monthly intravitreal injections and then were treated according to a TER of bevacizumab, ranibizumab, and/or aflibercept. The number of injections, BCVA, and central retinal thickness (CRT) were evaluated during the follow-up period. Results. 180 eyes from 180 patients were included in the study. Mean age was 75 ± 9 (range: 51–96). Mean BCVA was 0.77 ± 0.64 LogMAR at baseline, 0.69 ± 0.58 LogMAR (p=0.0057) after loading phase, 0.64 ± 0.55 LogMAR (p=0.0001) after 6 months of TER, and 0.76 ± 0.71 LogMAR after 6 years of treatment (n = 32 at year 6). CRT decreased significantly after the loading phase (p=0.0002). The mean number of intravitreal injections per year was 7.6 during the first three years of treatment and then decreased to 5.9 during year 4 to 7. Conclusions. This retrospective study of 180 nAMD patients treated with a TER of intravitreal anti-VEGF demonstrates an initial improvement of BCVA after loading phase, followed by long-term visual stabilization for at least six years. These results were obtained with a high number of injections, averaging close to six injections per year during long-term follow-up. In light of the natural evolution of nAMD, these data support the long-term efficacy of this treatment under real-world conditions of heterogeneity of patients and type of anti-VEGF used.http://dx.doi.org/10.1155/2020/3207614 |
| spellingShingle | Simon Javidi Ali Dirani Fares Antaki Marc Saab Sofiane Rahali Ghassan Cordahi Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up Journal of Ophthalmology |
| title | Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up |
| title_full | Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up |
| title_fullStr | Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up |
| title_full_unstemmed | Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up |
| title_short | Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up |
| title_sort | long term visual outcomes for a treat and extend antivascular endothelial growth factor regimen in eyes with neovascular age related macular degeneration up to seven year follow up |
| url | http://dx.doi.org/10.1155/2020/3207614 |
| work_keys_str_mv | AT simonjavidi longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegenerationuptosevenyearfollowup AT alidirani longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegenerationuptosevenyearfollowup AT faresantaki longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegenerationuptosevenyearfollowup AT marcsaab longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegenerationuptosevenyearfollowup AT sofianerahali longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegenerationuptosevenyearfollowup AT ghassancordahi longtermvisualoutcomesforatreatandextendantivascularendothelialgrowthfactorregimenineyeswithneovascularagerelatedmaculardegenerationuptosevenyearfollowup |